These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 33150526)

  • 1. A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model.
    Mahmood I
    Drugs R D; 2020 Dec; 20(4):377-387. PubMed ID: 33150526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Physiologically based pharmacokinetic modelling to predict exposure differences in healthy volunteers and subjects with renal impairment: Ceftazidime case study.
    Zhou L; Tong X; Sharma P; Xu H; Al-Huniti N; Zhou D
    Basic Clin Pharmacol Toxicol; 2019 Aug; 125(2):100-107. PubMed ID: 30739396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters.
    Hsueh CH; Hsu V; Zhao P; Zhang L; Giacomini KM; Huang SM
    Clin Pharmacol Ther; 2018 Mar; 103(3):485-492. PubMed ID: 28738449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comparative Study Between Allometric Scaling and Physiologically Based Pharmacokinetic Modeling for the Prediction of Drug Clearance From Neonates to Adolescents.
    Mahmood I; Tegenge MA
    J Clin Pharmacol; 2019 Feb; 59(2):189-197. PubMed ID: 30192373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delineating the Role of Various Factors in Renal Disposition of Digoxin through Application of Physiologically Based Kidney Model to Renal Impairment Populations.
    Scotcher D; Jones CR; Galetin A; Rostami-Hodjegan A
    J Pharmacol Exp Ther; 2017 Mar; 360(3):484-495. PubMed ID: 28057840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simplified PBPK modeling approach for prediction of pharmacokinetics of four primarily renally excreted and CYP3A metabolized compounds during pregnancy.
    Xia B; Heimbach T; Gollen R; Nanavati C; He H
    AAPS J; 2013 Oct; 15(4):1012-24. PubMed ID: 23835676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Model-Based Prediction of Pharmacokinetics in the Renal Impairment Population.
    Yee KL; Li M; Cabalu T; Sahasrabudhe V; Lin J; Zhao P; Jadhav P
    J Clin Pharmacol; 2018 Mar; 58(3):364-376. PubMed ID: 29077203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the single-dose pharmacokinetics of bilastine in subjects with various degrees of renal insufficiency.
    Lasseter KC; Sologuren A; La Noce A; Dilzer SC
    Clin Drug Investig; 2013 Sep; 33(9):665-73. PubMed ID: 23873362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ceftaroline Dosage Optimized for Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
    Zhou J; You X; Guo G; Ke M; Xu J; Ye L; Wu W; Huang P; Lin C
    J Clin Pharmacol; 2021 Dec; 61(12):1646-1656. PubMed ID: 34329494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients.
    Cui C; Li X; Liang H; Hou Z; Tu S; Dong Z; Yao X; Zhang M; Zhang X; Li H; Zuo X; Liu D
    Biopharm Drug Dispos; 2021 Jan; 42(1):24-34. PubMed ID: 33340419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Using PBPK Modeling to Predict Drug Exposure and Support Dosage Adjustments in Patients With Renal Impairment: An Example with Lamivudine.
    Shah K; Fischetti B; Cha A; Taft DR
    Curr Drug Discov Technol; 2020; 17(3):387-396. PubMed ID: 30767745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
    You X; Wu W; Xu J; Jiao Z; Ke M; Huang P; Lin C
    J Clin Pharmacol; 2020 Aug; 60(8):999-1010. PubMed ID: 32090332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Application of physiologically based pharmacokinetic modeling to predict the pharmacokinetics of telavancin in obesity with renal impairment.
    Wu W; Ke M; Ye L; Lin C
    Eur J Clin Pharmacol; 2021 Jul; 77(7):989-998. PubMed ID: 33447912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban-Renal and Hepatic Impairment and Drug-Drug Interaction Potential.
    Willmann S; Coboeken K; Kapsa S; Thelen K; Mundhenke M; Fischer K; Hügl B; Mück W
    J Clin Pharmacol; 2021 May; 61(5):656-665. PubMed ID: 33205449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Performance of Physiologically Based Pharmacokinetic and Population Pharmacokinetic Modeling of Renally Cleared Drugs in Children.
    Zhou W; Johnson TN; Xu H; Cheung S; Bui KH; Li J; Al-Huniti N; Zhou D
    CPT Pharmacometrics Syst Pharmacol; 2016 Sep; 5(9):475-83. PubMed ID: 27566992
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.
    De Sousa Mendes M; Hirt D; Urien S; Valade E; Bouazza N; Foissac F; Blanche S; Treluyer JM; Benaboud S
    Br J Clin Pharmacol; 2015 Nov; 80(5):1031-41. PubMed ID: 26011128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Mechanistic PBPK Model to Predict Renal Clearance in Varying Stages of CKD by Incorporating Tubular Adaptation and Dynamic Passive Reabsorption.
    Huang W; Isoherranen N
    CPT Pharmacometrics Syst Pharmacol; 2020 Oct; 9(10):571-583. PubMed ID: 32977369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance.
    Horiuchi K; Ohnishi S; Matsuzaki T; Funaki S; Watanabe A; Mizutare T; Matsumoto S; Nezasa KI; Hasegawa H
    J Pharm Sci; 2018 May; 107(5):1443-1453. PubMed ID: 29331382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic predictions for patients with renal impairment: focus on peptides and protein drugs.
    Czock D; Keller F; Seidling HM
    Br J Clin Pharmacol; 2012 Jul; 74(1):66-74. PubMed ID: 22242561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Predictive Value of Glomerular Filtration Rate-Based Scaling of Pediatric Clearance and Doses for Drugs Eliminated by Glomerular Filtration with Varying Protein-Binding Properties.
    Cristea S; Krekels EHJ; Allegaert K; Knibbe CAJ
    Clin Pharmacokinet; 2020 Oct; 59(10):1291-1301. PubMed ID: 32314184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.